Literature DB >> 28477848

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial.

Niki Katsiki1, Vasilios G Athyros1, Dimitri P Mikhailidis2, Christos Mantzoros3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28477848     DOI： 10.1016/j.metabol.2017.04.007

Source DB:  PubMed          Journal:  Metabolism        ISSN： 0026-0495            Impact factor:   8.694


× No keyword cloud information.
  2 in total

Review 1.  Lipid-lowering Drugs and Neurocognitive Function: A Systematic Review.

Authors:  Georgios Kyriakos; Lourdes Victoria Quiles-SÁnchez; Evangelos Diamantis; Paraskevi Farmaki; Nikolaos Garmpis; Christos Damaskos; Spyridon Savvanis; Alexandros Patsouras; Athanasia Stelianidi; Errika Voutyritsa; Vasiliki E Georgakopoulou; Anna Garmpi
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic.

Authors:  Niki Katsiki; Maciej Banach; Dimitri P Mikhailidis
Journal:  Arch Med Sci       Date:  2020-04-14       Impact factor: 3.318
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.